Abbott Laboratories (ABT)
Start the New Year Off With Passive Income: 3 Dividend Kings to Buy Now
Dividend stocks may boost your portfolio during any market environment. These particular companies have shown their commitment to dividend payments and growth over time.
Here's Why Abbott (ABT) Fell More Than Broader Market
In the latest trading session, Abbott (ABT) closed at $122.09, marking a -2.39% move from the previous day.
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Abbott issues US device correction for some glucose monitors over faulty readings risk
Abbott Laboratories said on Monday it has begun a correction in the United States for certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose monitoring sensors after internal testing showed some units may report falsely low glucose readings.
Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test
Abbott is getting into the cancer-testing game with its $21 billion acquisition of Cologuard test maker Exact Sciences.
Abbott to Acquire Exact Sciences for $21 Billion
Abbott agreed to acquire Exact Sciences for $105 a share, representing a total equity value of about $21 billion.
Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion.
Abbott Laboratories agrees to buy the cancer screening company in a cash deal.
Exact Sciences Stock Jumps on Reported Deal Interest From Abbott Laboratories
A report said the conglomerate Abbott Laboratories is close to a deal to acquire the company.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Why Is Abbott (ABT) Up 1.3% Since Last Earnings Report?
Abbott (ABT) reported earnings 30 days ago. What's next for the stock?
Goldman Sachs Says US Stocks Could Lag for 10 Years: 5 Strong Buy Value Dividend Ideas
Goldman Sachs has projected that U.S. stocks will deliver lackluster returns over the next decade primarily due to two key factors: extreme market concentration and elevated valuations.
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
